T cells directed against hematopoietic-restricted minor histocompatibility antigens (mHags) may mediate graft-versus-leukemia (GVL) reactivity without graft-versushost-disease. Recently, the HLA-A24-restricted mHag ACC-1 and the HLA-B44-restricted mHag ACC-2 encoded by separate polymorphisms within the BCL2A1 gene were characterized. Hematopoietic-restricted expression was suggested for these mHags. We demonstrate BCL2A1 expression in mesenchymal stromal cells (MSC), that was upregulated by inflammatory cytokines TNFα and/or IFNγ. Analysis of cytotoxicity and IFNγ production illustrated that ACC-2 specific T cells did not recognize untreated MSC or IFNγ-treated MSC, but showed specific recognition and killing of TNFα+IFNγ-treated MSC. We hypothesize that under steady-state
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Abstract
T cells directed against hematopoietic-restricted minor histocompatibility antigens (mHags) may mediate graft-versus-leukemia (GVL) reactivity without graft-versushost-disease. Recently, the HLA-A24-restricted mHag ACC-1 and the HLA-B44-restricted mHag ACC-2 encoded by separate polymorphisms within the BCL2A1 gene were characterized. Hematopoietic-restricted expression was suggested for these mHags. We demonstrate BCL2A1 expression in mesenchymal stromal cells (MSC) , that was upregulated by inflammatory cytokines TNFα and/or IFNγ. Analysis of cytotoxicity and IFNγ production illustrated that ACC-2 specific T cells did not recognize untreated MSC or IFNγ-treated MSC, but showed specific recognition and killing of TNFα+IFNγ-treated MSC. We hypothesize that under steady-state circumstances BCL2A1 specific T cells may exhibit relative specificity for hematopoietic tissue but reactivity against non-hematopoietic cells may occur when inflammatory infiltrates are present. Thus, the role of BCL2A1-specific T cells in differential induction of GVL reactivity and graft-versus-host-disease may depend on the presence of inflammatory responses that may occur during graft-versus-hostdisease.
Introduction
Allogeneic stem cell transplantation (SCT) and donor lymphocyte infusion (DLI) are effective treatments for patients with hematological malignancies, [1] [2] [3] [4] but can be complicated by graft-versus-host-disease (GVHD). 5, 6 Following HLA-identical SCT both the graft-versus-leukemia (GVL) effect and GVHD can be mediated by donorderived T cells recognizing polymorphic minor histocompatibility antigens (mHags) on recipient cells. Immunotherapy directed against mHags with hematopoietic-tissue restricted expression may eradicate the leukemic cells without inducing GVHD. 7 Recently, the HLA-A24-restricted mHag ACC-1 and the HLA-B44-restricted mHag ACC-2, encoded by separate polymorphisms within the BCL2A1 gene, were identified, and hematopoietic-restricted expression was suggested for these mHags. 8 However, in a retrospective analysis GVHD, relapse and disease-free survival were not statistically different between patients receiving ACC-1 compatible or incompatible transplantation. 9 Previous studies have indicated expression of the human BCL2A1 gene not only in hematopoietic cells, but also in non-hematopoietic tissues, including lung, small intestine and testis, and expression could be induced in endothelial cells by inflammatory cytokines TNFα and IL1β.
10-12
Induction of BCL2A1 expression in non-hematopoietic tissues by inflammatory cytokines may have important consequences for the role of T cells recognizing ACC-1 and ACC-2 in differential induction of GVL and GVHD. Local inflammatory cytokine production can be triggered by T cells recognizing host APC in non-hematopoietic tissues.
13-15
In this study, we characterized the recognition pattern of mHag ACC-2-specific T cells isolated from a patient during a combined GVHD and GVL response after DLI.
We show that ACC-2-specific T cells recognized not only leukemic cells but also nonhematopoietic cells under inflammatory conditions, and therefore could play a role in the etiology of GVHD. 
Study Design
Isolation of T cell clones and cell culture
Cytotoxic T lymphocyte (CTL) clones were isolated from an HLA-A2 A3 B7 B44 positive male patient with relapsed chronic myeloid leukemia (CML) during a clinical response to DLI from his HLA-identical female donor. 16 EBV-transformed B cell lines (EBV-LCL) and phytohemagglutinin (PHA)-activated T cells (PHA blasts) were generated as described. 17 Mesenchymal stromal cells (MSC)
were derived from bone marrow of healthy donors or CML patients as previously described. 18 To induce gene expression in response to inflammatory cytokines, MSC
were cultured for 48 hours with 10 ng/ml TNFα and/or 100 IU/ml IFNγ (Boehringer 
Genotyping of BCL2A1 polymorphisms and quantitative real-time RT-PCR
RNA isolation and cDNA synthesis were performed as described. 19 A 311 bp amplication product containing all known BCL2A1 polymorphisms was generated using forward primer 5'-ttggatatatttacaggctggctca-3' and reverse primer 5'-gggcaatttgctgtcgtagaag-3'. PCR-products were sequenced as described. 20 Quantitative real-time RT-PCR for BCL2A1 was performed as described 21 using primers 5'-gtcccgtagacactgccagaacact-3' and 5'-ccattttcccagcctccgt-3' and probe 5'-
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Analysis of cytotoxicity and IFNγ production
To determine cytotoxicity, 51 Cr-release-assays were performed. 22 As effector cells, CTL clone 65 and the HLA-A2-specific control CTL clone MBM13 were used. To analyze cytotoxicity against ACC-2 peptide KEFEDDIINW or ACC-2 control peptide KEFEDGIINW, donor-derived EBV-LCL were loaded with 1 ug/ml peptide during 51 Cr-labeling. IFNγ production was measured as described.
16
Results and discussion
Recently, we isolated mHag-specific CTL clones from a male patient with relapsed CML during the clinical response to DLI from his HLA-identical female donor.
16, 23 The DLI induced a complete remission but was complicated by GVHD resulting in organ damage. Not only CTL clones specific for the mHags HA-1 and HY-B7 were isolated.
CTL clone 65 appeared to be specific for ACC-2 because it lysed donor-derived EBV-LCL labeled with ACC-2 peptide KEFEDDIINW ( Figure 1A ). For personal use only. on October 28, 2017. by guest www.bloodjournal.org From
